Antibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 27457-1-AP - Provider product page

- Provider
- Proteintech Group
- Product name
- RRAS antibody
- Antibody type
- Polyclonal
- Description
- RRAS antibody (Cat. #27457-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IHC, IP, WB,ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Immune Characteristics of eQTL and Gene Risk Model and the Inhibitory Effect of DCTD and RRAS on Ferroptosis in Glioblastoma.
Integrated multi-omics analyses of oral squamous cell carcinoma reveal precision patient stratification and personalized treatment strategies.
Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.
Polymeric nanoparticle mediated inhibition of miR-21 with enhanced miR-124 expression for combinatorial glioblastoma therapy.
Metabolism-induced tumor activator 1 (MITA1), an Energy Stress-Inducible Long Noncoding RNA, Promotes Hepatocellular Carcinoma Metastasis.
Identification of RRAS gene related to nasopharyngeal carcinoma based on pathway and network-based analyses.
Zhang L, Chen W, Huang W, Cheng H
Frontiers in bioscience (Landmark edition) 2025 Aug 30;30(8):42844
Frontiers in bioscience (Landmark edition) 2025 Aug 30;30(8):42844
Integrated multi-omics analyses of oral squamous cell carcinoma reveal precision patient stratification and personalized treatment strategies.
Wu CS, Li HP, Hsieh CH, Lin YT, Yi-Feng Chang I, Chung AK, Huang Y, Ueng SH, Hsiao YC, Chien KY, Luo JD, Chen CH, Liao WC, Hung JL, Yuan SN, OuYang CN, Chiang WF, Chien CY, Chuang HC, Chu LJ, Liu H, Yang CY, Robles AI, Rodriguez H, Lin HH, Yang HY, Hsueh C, Chang KP, Yu JS, Chang YS
Cancer letters 2025 Apr 1;614:217482
Cancer letters 2025 Apr 1;614:217482
Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.
Pucci P, Lee LC, Han M, Matthews JD, Jahangiri L, Schlederer M, Manners E, Sorby-Adams A, Kaggie J, Trigg RM, Steel C, Hare L, James ER, Prokoph N, Ducray SP, Merkel O, Rifatbegovic F, Luo J, Taschner-Mandl S, Kenner L, Burke GAA, Turner SD
Nature communications 2024 Apr 23;15(1):3422
Nature communications 2024 Apr 23;15(1):3422
Polymeric nanoparticle mediated inhibition of miR-21 with enhanced miR-124 expression for combinatorial glioblastoma therapy.
Liu Y, Zheng M, Jiao M, Yan C, Xu S, Du Q, Morsch M, Yin J, Shi B
Biomaterials 2021 Sep;276:121036
Biomaterials 2021 Sep;276:121036
Metabolism-induced tumor activator 1 (MITA1), an Energy Stress-Inducible Long Noncoding RNA, Promotes Hepatocellular Carcinoma Metastasis.
Ma M, Xu H, Liu G, Wu J, Li C, Wang X, Zhang S, Xu H, Ju S, Cheng W, Dai L, Wei Y, Tian Y, Fu X
Hepatology (Baltimore, Md.) 2019 Jul;70(1):215-230
Hepatology (Baltimore, Md.) 2019 Jul;70(1):215-230
Identification of RRAS gene related to nasopharyngeal carcinoma based on pathway and network-based analyses.
Xiao R, Shi L, Yang T, Zhang M, Wang H, Mai S
Translational cancer research 2019 Apr;8(2):664-675
Translational cancer research 2019 Apr;8(2):664-675
No comments: Submit comment
No validations: Submit validation data